Crossmark

COVID-19 Pandemic Impact on Diagnosis, Stage, and Treatment of Hepatocellular Carcinoma in the United States

Crossref DOI link: https://doi.org/10.1016/j.gastha.2023.11.011

Published Print: 2024

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Kaur, Bhupinder

Yeo, Yee Hui

Liang, Jeff

Luu, Michael

Ayoub, Walid

Kuo, Alexander

Trivedi, Hirsh

Sankar, Kamya

Gong, Jun

Hendifar, Andrew

Osipov, Arsen

Kosari, Kambiz

Nissen, Nicholas

Noureddin, Mazen

Singal, Amit G.

Yang, Ju Dong https://orcid.org/0000-0001-7834-9825
Funding

Funding for this research was provided by:

National Institutes of Health (K08CA259534)

U.S. Department of Defense (CA191051)

National Cancer Institute (R01 CA212008)

National Cancer Institute (R01 CA222900)

National Cancer Institute (U01 CA230694)
License Information

Text and Data Mining valid from 2024-01-01

Text and Data Mining valid from 2024-01-01

Version of Record valid from 2023-11-20
More Information

This article is maintained by: Elsevier

Article Title: COVID-19 Pandemic Impact on Diagnosis, Stage, and Treatment of Hepatocellular Carcinoma in the United States

Journal Title: Gastro Hep Advances

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.gastha.2023.11.011

Content Type: article

Copyright: © 2024 Published by Elsevier Inc. on behalf of the AGA Institute.